Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: A double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme
2014 ◽
Vol 50
(18)
◽
pp. 3125-3135
◽
Keyword(s):
Phase Ii
◽